This paper emphasizes the importance of distinguishing between the prevalence, incidence
and cumulative incidence of inhibitors in haemophilia A. Incidence and cumulative …

Factor VIII: C levels show a familial clustering, which remains after adjustment for the
influence of vWF and blood group. 46 Analysis of familial aggregation of factor VIII levels …

To elucidate the roles of the ABO blood group, von Willebrand factor (vWF), and clotting
factor VIII in the process of deep-vein thrombosis we undertook a population-based patient …

Since the 1970s, mortality in the hemophilia population has been dominated by human
immunodeficiency virus (HIV) and few reports have described mortality in uninfected …

The development of factor VIII: C inhibitors remains one of the most serious complications of
repeated transfusion in patients with haemophilia A. The proportion of patients affected has …

The objectives of this paper were to study the reported haemophilia A prevalence (per 100
000 males) on a country‐by‐country basis and address the following: Does the reported …

An active surveillance system was used to identify all residents with hemophilia in six US
states (Colorado, Georgia, Louisiana, Massachusetts, New York, and Oklahoma). A …

Background Treatment of patients with hemophilia has advanced over the past decades, but
it is unknown whether this has resulted in a normal life expectancy in the Netherlands …

Background: Clotting factor products have been safe for HIV since 1985, and for hepatitis C
since 1992. Few studies have reported on mortality in the total population of hemophilia …

Over the last decade we have witnessed an avalanche of newly identified risk factors for
venous thrombosis. This has advanced our knowledge of its etiology, because more …